Antiseizure Drugs in Epilepsy and Other Neurological Diseases

Antiseizure medications (ASMs), while primarily indicated for the treatment of epilepsy, are increasingly recognized for their therapeutic potential in a broad range of neurological and psychiatric conditions. This CME/CE course offers a focused exploration of ASMs used beyond epilepsy, providing healthcare professionals with the evidence-based knowledge needed to apply these treatments effectively in diverse clinical scenarios.

Participants will review the literature surrounding off-label use of ASMs in conditions such as migraine, bipolar disorder, neuropathic pain, anxiety, and fibromyalgia. Through an examination of randomized controlled trials, observational data, and clinical practice guidelines, learners will gain clarity on which ASMs are supported by substantial evidence versus those used based on clinical experience or mechanistic rationale.

The course also examines the pharmacodynamics and mechanisms of action of major ASMs—including sodium channel blockers, GABA modulators, calcium channel inhibitors, and glutamate antagonists. Understanding these mechanisms allows clinicians to match ASM properties with the pathophysiology of non-epileptic conditions.

Participants will learn how to optimize ASM selection and dosing when used off-label, including monitoring for side effects, drug interactions, and special population considerations. Case-based discussions highlight real-world applications of ASMs for managing comorbid epilepsy and mood disorders, chronic pain, and other complex presentations.

By the end of this activity, clinicians will be equipped to use ASMs judiciously, improving therapeutic precision and broadening their pharmacologic toolkit in the management of neurological and psychiatric disorders.

Educational Objectives

• Summarize current literature supporting off-label uses of antiseizure medications (ASMs) in neurology and psychiatry.
• Explain the pharmacologic mechanisms of ASMs and how they contribute to therapeutic effects beyond epilepsy.
• Apply strategies to optimize ASM use in off-label contexts, including individualized treatment planning, adverse effect management, and monitoring.

Who Should Do This Course?

This course is ideal for:

• Neurologists and Epileptologists utilizing ASMs for seizure and non-seizure indications.
• Psychiatrists managing mood disorders and anxiety with adjunctive ASM therapy.
• Internal Medicine and Primary Care Physicians addressing neuropathic pain, migraines, and behavioral conditions.
• Pediatric Neurologists treating neurodevelopmental conditions with overlapping psychiatric or seizure components.
• Nurse Practitioners, Physician Assistants, and Nurses managing medication regimens in chronic neurological care.

This course is beneficial for clinicians aiming to integrate ASMs into interdisciplinary treatment plans.

Did You Know?

• Topiramate and valproate are both FDA-approved for migraine prevention and supported by extensive clinical trial data. (Neurology, 2021)
• Gabapentin and pregabalin are first-line agents for treating neuropathic pain. (JAMA, 2019)
• Lamotrigine is effective in bipolar depression and is often used off-label for mood stabilization. (BJPsych, 2020)
• Levetiracetam has shown promise in treating behavioral disturbances in dementia and traumatic brain injury. (Epilepsy Currents, 2022)
• Over 40% of ASM prescriptions in neurology practices may involve off-label indications. (Annals of Neurology, 2020)